Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats

Molecular Pharmaceutics

Volumn 12, Issue 4, 2015, Pages 1062-1071

  Berthelsen, Ragna ^a   Holm, René ^a,b   Jacobsen, Jette ^a   Kristensen, Jakob ^c   Abrahamsson, Bertil ^d   Müllertz, Anette ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c Ferring Pharmaceuticals AS   (Denmark)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

bioavailability; Cremophor; fenofibrate; in vitro lipolysis; IVIVC; Kolliphor EL; Kolliphor ELP; Kolliphor RH40; micellar trapping; rats; surfactant digestion

Indexed keywords

FENOFIBRATE; KOLLIPHOR SURFACTANT; SURFACTANT; UNCLASSIFIED DRUG; CREMOPHOR; DRUG VEHICLE; EXCIPIENT; LIPID; MACROGOL DERIVATIVE; MICELLE; SOYBEAN OIL;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIGESTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIPOLYSIS; MAXIMUM PLASMA CONCENTRATION; MICELLE; NONHUMAN; PRIORITY JOURNAL; RAT; SOLUBILIZATION; ANIMAL; CHEMISTRY; INTESTINE ABSORPTION; MALE; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EXCIPIENTS; FENOFIBRATE; INTESTINAL ABSORPTION; LIPIDS; LIPOLYSIS; MALE; MICELLES; PARTICLE SIZE; PHARMACEUTICAL VEHICLES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SOYBEAN OIL; SURFACE-ACTIVE AGENTS;

EID: 84926644442     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500545k     Document Type: Article

References (35)

1. Williams, H. D.; Trevaskis, N. L.; Charman, S. A.; Shanker, R. M.; Charman, W. N.; Pouton, C. W.; Porter, C. J. H. Strategies to Address Low Drug Solubility in Discovery and Development Pharmacol. Rev. 2013, 65 (1) 315-499
2. Norinder, U.; Haeberlein, M. Calculated Molecular Properties and Multivariate Statisical Analysis in Absorption Prediction. In Drug Bioavailability. Estimation of Solubility, Permeability, Absorption and Bioavailability; van de Waterbeemd, H.; Lennernäs, H.; Artursson, P., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2003; pp 358-405.
3. Gibaldi, M.; Feldman, S. Mechanisms of surfactant effects on drug absorption J. Pharm. Sci. 1970, 59 (5) 579-589
4. Bardelmeijer, H. A.; Ouwehand, M.; Malingre, M. M.; Schellens, J. H.; Beijnen, J. H.; van, T. O. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut Cancer Chemother. Pharmacol. 2002, 49 (2) 119-125
5. Cuine, J. F.; Mcevoy, C. L.; Charman, W. N.; Pouton, C. W.; Edwards, G. A.; Benameur, H.; Porter, C. J. H. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs J. Pharm. Sci. 2008, 97 (2) 995-1012
6. Martin-Facklam, M.; Burhenne, J.; Ding, R.; Fricker, R.; Mikus, G.; Walter-Sack, I.; Haefeli, W. E. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL Br. J. Clin. Pharmacol. 2002, 53 (6) 576-581
7. Dahan, A.; Miller, J. M. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs AAPS J. 2012, 14 (2) 244-251
8. Ali, S.; Kolter, K. Challenges and Opportunies in Oral Formulation Development. Am. Pharm. Rev., posted Dec 10, 2012.
9. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 2001, 37 (13) 1590-1598
10. Christiansen, A.; Backensfeld, T.; Weitschies, W. Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes Eur. J. Pharm. Sci. 2010, 41 (2) 376-382
11. Sparreboom, A.; Van Zuylen, L.; Brouwer, E.; Loos, W. J.; De Bruijn, P.; Gelderblom, B.; Pillay, M.; Nooter, K.; Stoter, G.; Verweij, J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications Cancer Res. 1999, 59 (7) 1454-1457
12. Malingre, M. M.; Schellens, J. H.; van, T. O.; Ouwehand, M.; Bardelmeijer, H. A.; Rosing, H.; Koopman, F. J.; Schot, M. E.; Ten Bokkel Huinink, W. W.; Beijnen, J. H. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients Br. J. Cancer 2001, 85 (10) 1472-1477
13. Cuine, J. F.; Charman, W. N.; Pouton, C. W.; Edwards, G. A.; Porter, C. J. H. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs Pharm. Res. 2007, 24 (4) 748-757
14. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12 (3) 413-420
15. Granero, G. E.; Ramachandran, C.; Amidon, G. L. Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions Drug Dev. Ind. Pharm. 2005, 31 (9) 917-922
16. Persson, L. C.; Porter, C. J.; Charman, W. N.; Bergstrom, C. A. Computational prediction of drug solubility in lipid based formulation excipients Pharm. Res. 2013, 30 (12) 3225-3237
17. Balfour, J. A.; McTavish, D.; Heel, R. C. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia Drugs 1990, 40 (2) 260-290
18. Zhu, T.; Ansquer, J. C.; Kelly, M. T.; Sleep, D. J.; Pradhan, R. S. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans J. Clin. Pharmacol. 2010, 50 (8) 914-921
19. Borkar, N.; Xia, D.; Holm, R.; Gan, Y.; Mullertz, A.; Yang, M.; Mu, H. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium Eur. J. Pharm. Sci. 2014, 51, 204-210
20. Hanafy, A.; Spahn-Langguth, H.; Vergnault, G.; Grenier, P.; Grozdanis, M. T.; Lenhardt, T.; Langguth, P. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug Adv. Drug Delivery Rev. 2007, 59 (6) 419-426
21. Zangenberg, N. H.; Mullertz, A.; Kristensen, H. G.; Hovgaard, L. A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium Eur. J. Pharm. Sci. 2001, 14 (2) 115-122
22. Zangenberg, N. H.; Mullertz, A.; Kristensen, H. G.; Hovgaard, L. A dynamic in vitro lipolysis model. II: Evaluation of the model Eur. J. Pharm. Sci. 2001, 14 (3) 237-244
23. Cizek, L. J. Total water content of laboratory animals with special reference to volume of fluid within the lumen of the gastrointestinal tract Am. J. Physiol. 1954, 179 (1) 104-110
24. Fernandez, S.; Rodier, J. D.; Ritter, N.; Mahler, B.; Demarne, F.; Carriere, F.; Jannin, V. Lipolysis of the semi-solid self-emulsifying excipient Gelucire 44/14 by digestive lipases Biochim. Biophys. Acta 2008, 1781 (8) 367-375
25. Williams, H. D.; Sassene, P.; Kleberg, K.; Bakala-N'Goma, J. C.; Calderone, M.; Jannin, V.; Igonin, A.; Partheil, A.; Marchaud, D.; Jule, E.; Vertommen, J.; Maio, M.; Blundell, R.; Benameur, H.; Carriere, F.; Mullertz, A.; Porter, C. J.; Pouton, C. W. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations J. Pharm. Sci. 2012, 101 (9) 3360-3380
26. Matsaridou, I.; Barmpalexis, P.; Salis, A.; Nikolakakis, I. The influence of surfactant HLB and oil/surfactant ratio on the formation and properties of self-emulsifying pellets and microemulsion reconstitution AAPS PharmSciTech 2012, 13 (4) 1319-1330
27. Buch, P.; Langguth, P.; Kataoka, M.; Yamashita, S. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system J. Pharm. Sci. 2009, 98 (6) 2001-2009
28. Li, X.; Gu, L.; Xu, Y.; Wang, Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats Drug Dev. Ind. Pharm. 2009, 35 (7) 827-833
29. Sunesen, V. H.; Vedelsdal, R.; Kristensen, H. G.; Christrup, L.; Mullertz, A. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug Eur. J. Pharm. Sci. 2005, 24 (4) 297-303
30. Hirata, T.; Keto, Y.; Yamano, M.; Yokoyama, T.; Sengoku, T.; Seki, N. Inhibitory effect of ramosetron on corticotropin releasing factor- and soybean oil-induced delays in gastric emptying in rats J. Gastroenterol. Hepatol. 2012, 27 (9) 1505-1511
31. Hunt, J. N.; Stubbs, D. F. The volume and energy content of meals as determinants of gastric emptying J. Physiol 1975, 245 (1) 209-225
32. Palin, K. J. Effect of Oils on Drug Absorption; PhD thesis, Department of Pharmacy and Physiology and Pharmacology, University of Nottingham: 1981.
33. Thomas, N.; Richter, K.; Pedersen, T. B.; Holm, R.; Mullertz, A.; Rades, T. In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate AAPS J. 2014, 16 (3) 539-549
34. Miller, J. M.; Beig, A.; Krieg, B. J.; Carr, R. A.; Borchardt, T. B.; Amidon, G. E.; Amidon, G. L.; Dahan, A. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation Mol. Pharmaceutics 2011, 8 (5) 1848-1856
35. Ehrhardt, M.; Lindenmaier, H.; Burhenne, J.; Haefeli, W. E.; Weiss, J. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro Biochem. Pharmacol. 2004, 67 (2) 285-292